Is Risk Malignancy index a useful tool for predicting malignant ovarian masses in developing countries? by Aziz, Aliya & Najmi, Nida
eCommons@AKU
Department of Obstetrics & Gynaecology Division of Woman and Child Health
January 2015
Is Risk Malignancy index a useful tool for
predicting malignant ovarian masses in developing
countries?
Aliya Aziz
Aga Khan University, aliya.aziz@aku.edu
Nida Najmi
Aga Khan University, nida.najmi@aku.edu
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_obstet_gynaecol
Part of the Obstetrics and Gynecology Commons, and the Women's Health Commons
Recommended Citation
Aziz, A., Najmi, N. (2015). Is Risk Malignancy index a useful tool for predicting malignant ovarian masses in developing countries?.
Obstetrics and Gynecology International, 2015.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_obstet_gynaecol/81
Research Article
Is Risk Malignancy Index a Useful Tool for Predicting Malignant
Ovarian Masses in Developing Countries?
Aliya B. Aziz and Nida Najmi
Department of Obstetrics and Gynaecology, Aga Khan University Hospital, Karachi 74800, Pakistan
Correspondence should be addressed to Aliya B. Aziz; azizaliya@hotmail.com
Received 28 March 2015; Accepted 14 June 2015
Academic Editor: Enrique Hernandez
Copyright © 2015 A. B. Aziz and N. Najmi. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction. Risk of Malignancy Index (RMI) is widely studied for prediction of malignant pelvic masses in Western population.
However, little is known regarding its implication in the developing countries. The objective of this study is to determine how
accurately the RMI can predict the malignant pelvic masses.Materials and Methods. The study is a retrospective review of patients
attending the gynecological clinic between January 2004 and December 2008 with adnexal masses. Information on demographic
characteristics, ultrasound findings, menopausal status, CA125, and histopathology was collected. RMI score for each patient in
the study group was calculated. Results. The study group included a total of 283 patients. Analysis of the individual parameters of
RMI revealed that ultrasound was the best predictor of malignancy with a sensitivity, specificity, and positive likelihood ratio of
78.3%, 81.5%, and 4.2, respectively. At a standard cut-off value of 250, RMI had a positive likelihood ratio of 8.1, while it was 6.8 at a
cut-off of 200, albeit with comparable sensitivity and specificity. Conclusion. RMI is a sensitive tool in predicting malignant adnexal
masses. A cut-off of 200 may be suitable in developing countries for triaging and early referral to tertiary care centers.
1. Introduction
Ovarianmasses are a frequent cause of gynecological consults
and are often detected during imaging studies or exploratory
surgery for evaluation of abdominal or pelvic pain syn-
dromes. They occur across age groups and could result from
benign or malignant disease. With more than 250,000 new
cases reported every year, ovarianmalignancies represent the
fourth commonest cause of cancer deathsworldwide [1].They
also have the lowest 5-year survival rate (30–50%) among
all gynecological cancers [2]. A recent report indicated an
increasing incidence of ovarian cancers in the developing
world, compared to the developed countries [3].
Early identification of ovarian carcinomas and referral
to a gyneco-oncologist can facilitate accurate staging of
the disease and optimal cytoreductive treatment, enhancing
patient survival [4, 5]. Histopathology remains the diagnostic
gold standard for this cancer, and a definitive biomarker has
not been identified yet. Risk of Malignancy Index (RMI),
which considers the serum CA125 level, menopausal status,
and ultrasonographic findings in predicting malignant pelvic
masses, is widely employed in the developed countries [6].
However, its utility in risk prediction in the developing
countries is currently unknown.
The present study evaluated how accurately the RMI can
predict the risk of malignant pelvic masses, among patients
with an ovarian mass.
2. Material and Methods
After the approval of our institutional review board we
conducted a retrospective review of the case files of patients
with adnexal masses who attended the Gynecological Clinic
at the Aga Khan University, Karachi, Pakistan, between
January 2004 and December 2008. The International Clas-
sification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) criteria were used to identify adnexal masses.
Patients with advanced disease were excluded from the study.
We collected information on demographic characteristics,
ultrasonographic findings, menopausal status, serum CA125
level, and histopathology. The RMI for each patient was
calculated using the standard formula [6].
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3. Results
3.1. Demographic Data. The study group consisted of a total
of 283 patients. The age of the patients varied from 8 to 85
years (mean, 38.6 years). Premenopausal patients predomi-
nated in our study with 227 (80.8%) cases, while 54 (19.2%)
of the affected patients were in the postmenopausal group.
3.2. Ultrasonography Findings. Two hundred and seven
(73.7%) patients had a transabdominal ultrasonography for
diagnosis, while transvaginal ultrasonography detected the
disease in 74 (26.3%) cases. Table 1 shows the summary of
ultrasound findings in our patients.
3.2.1. Laterality of Lesion. The investigation revealed a unilat-
eral cyst in 252 (89.7%) cases, while 29 (10.3%) had bilateral
cysts.
3.2.2. Loculation. The lesions were multilocular in 166 (59%)
patients and unilocular in 115 (41%).
3.2.3. Echogenicity. Solid areas were absent in the lesions in
196 (69.8%) patients, while these were detected in 85 (30.2%)
patients.
3.2.4. Evidence of Metastasis. The majority of patients (272,
96.8%) had no evidence of metastasis, while 9 (3.2%) had
metastatic disease.
3.2.5. Presence of Ascites. Ascites was present in only 19
(6.8%) patients.
3.2.6. Ultrasound Score. We assigned scores of 0 (absence of
specific findings), 1 (presence of one finding), or 3 (two or
more findings) to the subjects, depending on the ultrasound
findings. One hundred and nineteen (42.3%) cases had an
ultrasound score of 1, while lesions of 88 (31.3%) and 74
(26.3%) patients were scored 0 and 3, respectively. Of the
207 (73.6%) patients with an ultrasound score 1, 196 (69.7%)
had benign disease, while 8 (2.8%) and 3 (1%) had malignant
and borderline disease, respectively. Seventy-four (26.3%)
patients in our series had an ultrasound score of 3, and among
them, 41 (14.5%) had benign, 29 (10.3%) had malignant, and
4 (1.4%) had borderline disease, respectively.
3.2.7. Ovarian Size. Ovarian size varied from 3 to 73 cm
(mean, 10.5 cm).
3.3. Histopathology Findings. As shown in Table 2, 237
(84.3%) patients had benign lesions, while 37 (13.2%) had
a malignant disease. Seven (2.5%) patients under 60 years
of age had borderline lesions. One hundred and thirty-nine
(49.4%) of the benign tumours occurred in patients aged 20 to
39 years, and 60 (21.3%) cases were in those aged 41–59 years.
Patients aged ≤20 years and ≥60 years reported 24 (8.5%)
and 14 (4.9%) cases of benign disease, respectively. Malignant
disease peaked in the age group 40–59 years with 21 (7.4%)
cases, while 10 (3.5%), 4 (1.4%), and 2 (0.7%) cases occurred
among patients aged ≥60 years, 20–39 years, and ≤20 years,
Table 1: Summary of ultrasound findings in the study.
Frequency Percentage (%)
Transabdominal scan 207 73.7
Transvaginal scan 74 26.3
Unilateral cyst 252 89.7
Bilateral cyst 29 10.3
Unilocular cyst 115 41.0
Multilocular cyst 166 59.0
Presence of solid areas 85 30.2
Absence of solid areas 196 69.8
Evidence of metastasis present 9 3.2
Evidence of metastasis absent 272 96.8
Presence of ascites 19 6.8
Absence of ascites 262 93.2
Ultrasound score 0 88 31.3
Ultrasound score 1 119 42.3
Ultrasound score 3 74 74
Table 2: Distribution of cases in the study.
Benign
(%)
Borderline
(%)
Malignant
(%) Total (%)
Histopathology 237 (84.3) 7 (2.5) 37 (13.2) 281
Age (years)
≤20 24 (8.5) 1 (0.3) 2 (0.7) 27 (9.6)
20–39 139 (49.4) 3 (1.0) 4 (1.4) 146 (51.9)
40–59 60 (21.3) 3 (1.0) 21 (7.4) 84 (29.8)
≥60 14 (4.9) 0 (0) 10 (3.5) 24 (8.5)
Premenopausal 203 (72.2) 6 (2.1) 18 (6.4) 227 (80.7)
Postmenopausal 34 (12.0) 1 (0.3) 19 (6.7) 54 (19.2)
Ultrasound score 1 196 (69.7) 3 (1.0) 8 (2.8) 207 (73.6)
Ultrasound score 3 41 (14.5) 4 (1.4) 29 (10.3) 74 (26.3)
CA125 ≥ 35 75 (26.6) 4 (1.4) 26 (9.2) 105 (37.3)
Ca125 < 35 162 (57.6) 3 (1.0) 11 (3.9) 176 (62.6)
RMI groups
≤25 117 (41.6) 0 (0) 3 (1.0) 120 (42.7)
25.1–249.9 106 (37.7) 5 (1.7) 14 (4.9) 125 (44.4)
≥250 14 (4.9) 2 (0.7) 20 (7.1) 36 (12.8)
respectively.Three cases of borderline disease occurred in the
age groups 21–39 and 40–59 years, and one (0.3%) case was in
awoman aged≤20 years, while such lesions were not detected
in women ≥60 years. Two hundred and three (72.2%) of
the 227 premenopausal patients had benign disease, while 18
(6.4%) had malignant, and 6 (2.1%) had borderline lesions.
Among the 54 (19.2%) postmenopausal patients, 34 (12%) had
benign disease, while 19 (6.7%) and 1 (0.3%) had malignant
and borderline disease, respectively.
3.4. Serum CA125 Levels. The serum CA125 levels in the
patients varied from 1.2 to 6803U/mL (mean, 197U/mL)
(Table 2). One hundred and seventy-six (62.6%) patients had
a serum CA125 level less than 35U/mL, while the levels
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Table 3: Diagnostic performance of the different RMI cut-offs employed.
RMI cut-off value Sensitivity Specificity PPV NPV +LR ratio −LR ratio
250 54.05 (20/37) 93.4 (228/244) 55.5 (20/36) 93.06 (228/245) 8.1 0.49
200 53.8 (21/39) 92.2 (225/244) 52.5 (21/40) 92.5 (225/243) 6.8 0.50
150 61.5 (24/39) 89.3 (218/244) 48.0 (24/50) 93.5 (218/233) 5.7 0.43
100 66.6 (26/39) 84.0 (205/244) 40.0 (26/65) 94.0 (205/218) 4.1 0.39
Table 4: Diagnostic performance of the criteria evaluated.
Sensitivity % Specificity % PPV (%) NPV (%) +ve likelihood ratio −ve likelihood ratio
RMI ≥ 250 54.05 (20/37) 93.4 (228/244) 55.5 (20/36) 93.06 (228/245) 8.1 0.49
CA125 ≥ 35 70.2 (26/37) 67.6 (165/244) 24.7 (26/105) 93.7 (165/176) 2.1 0.44
Ultrasound score 3 78.3 (29/37) 81.5 (199/244) 39.1 (29/74) 96.1 (199/207) 4.2 0.26
Menopause score 3 51.3 (19/37) 85.6 (209/244) 35.1 (19/54) 92.0 (209/227) 3.5 0.56
were higher in 105 (37.3%) patients. Among the patients with
CA125 levels greater than 35U/mL, 75 (26.6%) had benign
disease, 26 (9.2%) hadmalignant, and 4 (1.4%) had borderline
lesions. One hundred and sixty-two (57.6%) patients with
CA125 levels less than 35U/mL had benign lesions, while 11
(3.9%) had malignant, and 3 (1%) had borderline disease.
3.5. RMI. The RMI was calculated according to a standard
formula (Jacobs et al., 1990). The RMI scores of the patients
varied from 1.9 to 32364 (mean, 601.1 ± 3196.3) (Table 2).
Two hundred and forty-five (87.1%) patients had an RMI
score less than 250, while 36 (12.8%) had scores above 250.
Twenty of the patients with RMI scores ≥250 had malignant
disease, while 14 had benign and 2 had borderline lesions.
Among patients with RMI scores less than 250, 223 (79.3%)
had benign disease, while 17 (6%) and 5 (1.7%) hadmalignant
and borderline lesions, respectively.
3.6. Risk Stratification Based on RMI Scores. We assessed the
distribution of benign, borderline, and malignant ovarian
cancers when the patients were categorized based on their
RMI scores.
In order to identify the RMI score that was an effective
risk predictor, we studied the sensitivity and specificity of
RMI scores at four levels, namely, ≤100, ≤150, ≤200, and
≤250. The sensitivity, specificity, and positive and negative
predictive values of RMI score at each of these levels are
summarized in Table 3.
One hundred and twenty (42.7%) patients had RMI
scores ≤25, among whom 117 (41.6%) had benign disease, 3
(1%) hadmalignant disease, and none had borderline lesions.
The scores ranged from 25.1 to 249 in 125 (42.7%) patients.
In this group, 106 (37.7%) patients had benign disease and 5
(1.7%) had borderline disease, while 14 (4.9%) had malignant
disease. In the third group with RMI scores ≥ 250, 20 (7.1%)
had malignant disease, 2 (0.7%) had borderline disease, and
14 (4.9%) had benign disease.
To find out the RMI score that could most effectively
classify the disease, we calculated the sensitivity, specificity,
positive predictive value, negative predictive value, and the
likelihood ratios at RMI cut-off levels of 100, 150, 200, and
250. A comparison of the diagnostic indices with these cut-
offs is shown in Table 3.
As shown in Table 3, an RMI of 250 yielded the ideal
combination of sensitivity (54.05), specificity (93.4), positive
predictive value (55.5), negative predictive value (93.06), and
positive (8.1) and negative (0.49) likelihood ratios. Though
cut-offs of 100 and 150 showed higher sensitivity in detecting
malignant disease, they had lower specificity, positive predic-
tive value, and likelihood ratios, compared to 250.
We also compared the diagnostic performance of RMI
scores >250 against CA125 levels >35U/mL, ultrasound score
of 3 and menopausal score of 3. Table 4 summarizes the
findings from this analysis. Among the three criteria, an
ultrasound score of 3 had the highest sensitivity (78.3%),
while an RMI score ≥250 had the highest specificity (93.4%).
The latter also had the highest positive predictive value of
55.5%, while negative predictive value was highest for an
ultrasound score of 3 (96.1%). The positive likelihood ratio
was highest for RMI score ≥250, while a score of 100 had the
least negative likelihood ratio (0.39).
4. Discussion
About 10% of women undergo exploratory surgery for eval-
uation of ovarian masses during their lifetime [7]. Prompt
identification of ovarian malignancies and referral to a
gyneco-oncologist can enhance the patient survival rates [8],
but a single method which can accurately predict ovarian
malignancy is still unavailable. Herein we report that the
multiparametric RMI score can be a useful tool in prediction
of malignant ovarian disease, in low-resource settings.
The mean age of the patients with ovarian mass in our
study was 36.87 years (range, 8 to 85 years). This is slightly
higher than that reported in a similar study by Akdeniz et al.
in 2009 [9].
In our study, 13.2% of the patients with an ovarian mass
had malignant disease. Thirty-five percent of malignancies
occurred in postmenopausal patients and 7.9% among the
premenopausal patients. The data seem to agree with earlier
reports of similar incidence rates and preponderance in
postmenopausal patients [9–12].
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Ultrasonography is widely appreciated as the best imag-
ing method for evaluation of ovarian pathology. Several
groups have reported higher sensitivity, specificity, and pos-
itive predictive values for this method (Agarwal et al., 2011,
and references therein). In our study, an ultrasound score of
3 had the highest sensitivity (78.3%) and negative predictive
value (96.1%) and the least negative likelihood ratio (0.26),
among the parameters evaluated.
Several candidate biomarkers and their combinations
have been employed in assessing the risk of ovarian malig-
nancies, albeit with varying efficiency [13]. SerumCA125 level
is widely appreciated as a useful biomarker for estimating the
risk of ovarian cancer, though other gynecological pathology
can also increase its levels. Myers et al. [14] have earlier
reported sensitivity and specificity of less than 80%, for this
marker, in the prediction of ovarian cancers. Simsek et al.
(2014) [15] reported a sensitivity of 78.6% and specificity
of 63.5% for a CA125 cut-off of 35U/mL. Another report
indicated a sensitivity of 88% and specificity of 97% for CA125
at a higher cut-off of 88U/mL [12]. In our study, CA125 levels
≥35U/mL had a sensitivity of 70.2%, specificity of 67.6%,
positive predictive value of 24.7%, negative predictive value
of 93.7, and positive and negative likelihood ratios of 2.1 and
0.44, respectively. We suggest that a higher prevalence of
inflammatory and nonspecific uterine and ovarian pathology
might have contributed to elevated CA125 levels in themajor-
ity of our patients and thus its low diagnostic performance in
the detection of malignant ovarian disease.
Rao (2014) [16] has recently reported higher sensitivity,
specificity, and positive and negative predictive values for
a postmenopausal score of 3. In our study, this parameter
had a higher specificity and negative predictive value, but
lower sensitivity and positive predictive values in assessing
malignancy risk.
RMI was first proposed by Jacobs et al. and is calculated
from the serum CA125 antigen level, menopausal status,
and ultrasonographic findings [6]. Several retrospective and
prospective studies have reported it to be the best available
tool for triage and referral of ovarian malignancies [17, 18].
Its utility as a diagnostic tool depends on the prevalence of
malignancy in the study population [15]. We observed a low
prevalence of malignancy (13.2%) among our study group,
significantly lesser than some of the earlier reports of 30–43%
[6, 17, 19].
Jacobs et al. (1990) [6], studying 143 patients, reported a
sensitivity of 85.4% and specificity of 96.9% for this method,
with a cut-off of 200. Subsequently, several groups have
reported its superior sensitivity and specificity in estimating
the risk of ovarianmalignancy, compared to other parameters
[19–25]. The RMI cut-offs in many studies ranged from 25
to 250 (reviewed in Geomini et al., 2009) [18]. Most studies
reported an increased diagnostic accuracy and performance
with an RMI cut-off of 200 [6, 16, 19, 20, 22, 24, 26–32].
A recent study reported a sensitivity of 89.5%, specificity
of 96.2%, positive predictive value of 77.3%, and negative
predictive value of 98.4% [11], when a higher RMI cut-off
of 238 was used for the screening. Yamamoto et al. (2009)
[25] reported a sensitivity and specificity of 75% and 91%,
respectively, using a cut-off of 450. The best performance
in the present study was seen with an RMI cut-off of 250,
and the low sensitivity (54.5%) and high specificity (93.4%)
observed were comparable to the majority of earlier reports
that employed a similar cut-off [6, 19, 20, 22, 26, 29–35].
We conclude that, in the absence of a definitive biomarker,
the multiparametric Risk of Malignancy Index serves as
a very useful tool for identification of malignant ovarian
disease and their prompt triage and referral to expert care.
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